TRAIL and its receptors are associated with many cardiovascular risk factors including smoking, coronary artery disease (CAD) and diabetes (Benedict and Ware, 2012; Cheng et al., 2015; di Giuseppe et al., 2017; Mattisson et al., 2017; Hameed et al., 2012). Here, TNFSF10 is linked to coronary artery disorder.